Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence